Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02CZK
|
|||
| Former ID |
DNCL002635
|
|||
| Drug Name |
Karenitecin
|
|||
| Synonyms |
Karenitecin (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lung cancer [ICD-11: 2C25.0] | Phase 3 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 3 | [1] | ||
| Company |
BioNumerik Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H28N2O4Si
|
|||
| Canonical SMILES |
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[Si](C)(C)C)O
|
|||
| InChI |
1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
|
|||
| InChIKey |
POADTFBBIXOWFJ-VWLOTQADSA-N
|
|||
| CAS Number |
CAS 203923-89-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase (TOP) | Target Info | Inhibitor | [2] |
| DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [3] | |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.